

Literatur zum Titelthema

„Neu in der Frauenheilkunde/speziellen gynäkologischen Onkologie“

von Privatdozent Dr. Matthias Kiesel, Privatdozent Dr. Joachim Diessner, Dr. Jessica Salmen, Privatdozentin Dr. Tanja Schläiß, MHBA, Professorin Dr. Christine Wulff und Professor Dr. Achim Wöckel

Bayerisches Ärzteblatt 3/2024, Seite 64 ff.

1. Beckmann, M., Fehm, T., *S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom*. Leitlinienprogramm Onkologie, 2021. **Langversion 2.2 – März 2022 AWMF-Registernummer: 032/033OL**.
2. Peter Hillemanns, K.F., *S3-Leitlinie Prävention des Zervixkarzinoms*. 2020. **Langversion 1.1 – März 2020 AWMF-Registernummer 015/027OL**.
3. Ramirez PT, F.M., Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, GebSKI V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A, *Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer*. *N Engl J Med.*, 2018. **379**(20): p. 1895-1904.
4. Marie Plante, J.S.K., Sarah Ferguson, Vanessa Samouëlian, Gwenael Ferron, Amandine Maulard, Cor de Kroon, Willemien Van Driel, John Tidy, Christian Marth, Karl Tamussino, Stefan Kommos, Frederic Goffin, Brynhildur Eyjólfsdóttir, Jae-Weon Kim, Noreen Gleeson, Juliana M Ubi, Lori Brotto, Dongsheng Tu, and Lois E. Shepherd, *An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE)*. *Journal of Clinical Oncology*, 2023. **41:17**
5. Michael Höckel, L.-C.H., Norma Manthey, Ulf-Dietrich Braumann, Ulrich Wolf, Gero Teichmann, Katrin Frauenschläger, Nadja Dornhöfer, Jens Eienkel, *Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis*. *Lancet Oncol.*, 2009. **10**(7): p. 683-92.
6. Paul Buderath, M.S., Wencke Ruhwedel, Devis Strutas, Gabriele Feisel-Schwickardi, Pauline Wimberger, Rainer Kimmig, *Total mesometrial resection (TMMR) for cervical cancer FIGO IB-IIA: first results from the multicentric TMMR register study*. *J Gynecol Oncol.*, 2022. **33**(1).
7. D. Lorusso, Y.X., K. Hasegawa and M.H.L.G. G. Scambia, P. Ramos Elias, A. Acevedo, J. Vizkeleti, A.J.P.D.S. Gomes, F. Contreras Mejia, A. Reiss, A. Ayhan, J.-Y. Lee, V. Saevets, F. Zagouri, K. Li, K. Ussui Yamada, S. Toker, S. Pignata, L.R. Duska, *Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study*. *Annals of Oncology*, 2023. **34**: p. 1279-S1280.
8. M. McCormack, D.G.R., G. Eminowicz, P. Diez, L. Farrelly, C. Kent, E. Hudson, M. Panades, T. Mathews, A. Anand, M. Persic, J. Forrest, R. Bhana, N. Reed, A. Drake, H. Stobart, A. Mukhopadhyay, A.M. Hacker and J.A.L. A. Hackshaw, *A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial*. *Annals of Oncology*, 2023. **34**: p. 1276.
9. Bradley J Monk, K.S.T., Coraline Dubot, M Valeria Caceres, Kosei Hasegawa, Ronnie Shapira-Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Kan Li, Allison Martin Nguyen, Matthew J Monberg, Nicoletta Colombo, Domenica Lorusso, *Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial*. *Lancet Oncol.*, 2023. **24**(4): p. 392-402.
10. I.B. Vergote, A.G.M., K. Fujiwara, E. Kalbacher, A. Bagameri, J.-Y.L. S. Ghamande, S. Banerjee, F.C. Maluf, D. Lorusso, K. Yonemori, and L.M.M.S. E. Van Nieuwenhuysen, L.

- Woelber, A.M. Westermann, A. Covens, E. Whalley, M.S.L. Teng, I. Soumaoro, B.M. Slomovitz, *InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer*. *Annals of Oncology*, 2023. **34**: p. 1276-1277.
11. Krishnansu S. Tewari, M.D., Bradley J. Monk, M.D., Ignace Vergote, M.D., Austin Miller, Ph.D., Andreia C. de Melo, M.D., Ph.D., Hee-Seung Kim, M.D., Yong Man Kim, M.D., Ph.D., Alla Lisyanskaya, M.D., Ph.D., Vanessa Samouëlian, M.D., Ph.D., Domenica Lorusso, M.D., Ph.D., Fernanda Damian, M.D., Chih-Long Chang, M.D., Ph.D., Evgeniy A. Gotovkin, M.D., Shunji Takahashi, M.D., Ph.D., Daniella Ramone, M.D., Joanna Pikiel, M.D., Beata Maćkowiak-Matejczyk, M.D., Eva M. Guerra Alía, M.D., Nicoletta Colombo, M.D., Yulia Makarova, M.D., Danny Rischin, M.D., Stephanie Lheureux, M.D., Ph.D., Kosei Hasegawa, M.D., Ph.D., Keiichi Fujiwara, M.D., Ph.D., Jingjin Li, Ph.D., Shaheda Jamil, M.D., Vladimir Jankovic, M.D., Chieh-I Chen, M.P.H., Frank Seebach, M.D., David M. Weinreich, M.D., George D. Yancopoulos, M.D., Ph.D., Israel Lowy, M.D., Ph.D., Melissa Mathias, M.D., Matthew G. Fury, M.D., Ph.D., and Ana Oaknin, M.D., Ph.D., *Survival with Cemiplimab in Recurrent Cervical Cancer*. *N Engl J Med.*, 2022. **386**(6): p. 544-555.
 12. Meric-Bernstam F, M.V., Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY, *Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial*. *J Clin Oncol.*, 2024. **42**(1): p. 47-58.
 13. *Konsultationsfassung Endometriumkarzinom*. 2023 [cited 2023 16.12.2023]; 3.01: [
 14. Mirza, M.R., et al., *Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer*. *N Engl J Med*, 2023. **388**(23): p. 2145-2158.
 15. Eskander, R.N., et al., *Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer*. *N Engl J Med*, 2023. **388**(23): p. 2159-2170.
 16. N. Colombo, K.H., E. Hudson, F. Galli, Y. Antill, C.H. Choi, M. Rabaglio, F. Marmé, E. Petru, C-H. Lai, E. Biagioli, L. Fariñas Madrid, K. Takehara, K. Allan, Y.C. Lee, E. Piovano, C. Zamagni, G. Tasca, A. Ferrero, and M.P.B. Ginesta, *Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma*, in *ESMO2023*. 2023.
 17. Westin SN, M.K., Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. , *Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial*. . *J Clin Oncol.* , 2023.
 18. Matei DE, E.D., Kudrimoti M, et al., *Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma*. , in *SGO Annual Meeting on Women's Cancer*. 2023.
 19. O'Malley, D.M., et al., *Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study*. *J Clin Oncol*, 2022. **40**(7): p. 752-761.
 20. Oaknin, A., et al., *Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study*. *Clin Cancer Res*, 2023. **29**(22): p. 4564-4574.
 21. Makker, V., et al., *Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775*. *J Clin Oncol*, 2023. **41**(16): p. 2904-2910.
 22. Meric-Bernstam, F., et al., *Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial*. *J Clin Oncol*, 2023: p. JCO2302005.

23. Alessandro Santin, B.M., Eric R. Siegel, Justin Harold, Levent Mutlu, Gary Altwerger, Gloria S. Huang, Vaagn Andikyan, Mitchell B. Clark, Elena Ratner, Masoud Azodi, Peter Dottino, Peter E. Schwartz, Stefania Bellone, *Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2*. *Journal of Clinical Oncology*, 2023. **41**(16).
24. (DGGG), D.G.f.r.G.k.u.G.e.V. *Konsultationsfassung Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren*. 2024 [cited 2024 07.01.2024]; 6.01:[]
25. Harter P, S.J., Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A, *A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms*. *N Engl J Med*, 2019. **380**(9): p. 822-832.
26. Robert A. Burger, M.D., Mark F. Brady, Ph.D., Michael A. Bookman, M.D., Gini F. Fleming, M.D., Bradley J. Monk, M.D., Helen Huang, M.S., Robert S. Mannel, M.D., Howard D. Homesley, M.D., Jeffrey Fowler, M.D., Benjamin E. Greer, M.D., Matthew Boente, M.D., Michael J. Birrer, M.D., Ph.D., and Sharon X. Liang, M.D., *Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer*. *N Engl J Med.*, 2011. **365**(26): p. 2473-2483.
27. Isabelle Ray-Coquard, M.D., Ph.D., Patricia Pautier, M.D., Sandro Pignata, M.D., Ph.D., David Pérol, M.D., Antonio González-Martín, M.D., Ph.D., Regina Berger, Ph.D., Keiichi Fujiwara, M.D., Ph.D., Ignace Vergote, M.D., Ph.D., Nicoletta Colombo, M.D., Johanna Mäenpää, M.D., Ph.D., Frédéric Selle, M.D., Jalid Sehouli, M.D., Domenica Lorusso, M.D., Eva M. Guerra Alía, M.D., Alexander Reinthaller, M.D., Shoji Nagao, M.D., Ph.D., Claudia Lefeuvre-Plesse, M.D., Ulrich Canzler, M.D., Giovanni Scambia, M.D., Alain Lortholary, M.D., Frederik Marmé, M.D., Pierre Combe, M.D., Nikolaus de Gregorio, M.D., Ph.D., Manuel Rodrigues, M.D., Ph.D., Paul Buderath, M.D., Coraline Dubot, M.D., Alexander Burges, M.D., Benoît You, M.D., Eric Pujade-Lauraine, M.D., Ph.D., and Philipp Harter, M.D., Ph.D, *Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer*. *N Engl J Med.*, 2019. **381**(25): p. 2416-2428.
28. González-Martín A, P.B., Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Ceirbhail RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, *Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer*. *N Engl J Med.* , 2019. **381**(25): p. 2391-2402.
29. Moore K, C.N., Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P, *Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer*. *N Engl J Med.*, 2018. **379**(26): p. 2495-2505.
30. Philipp Harter, M.B., Nicoletta Colombo, Anne Floquet, Maria Jesús Rubio Pérez, Jae-Weon Kim, Stephanie Lheureux, Christian Marth, Gitte-Bettina Nyvang, Aikou Okamoto, Alexander Reuss, Giovanni Scambia, Fabian Trillsch, Mehmet Ali Vardar, Els Van Nieuwenhuysen, Jasmine Lichfield, Paul Rugman, Philip Twumasi-Ankrah, Carol Aghajanian, *DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients*. *Journal of Clinical Oncology*, 2019. **37**(15).
31. Westin, S., Michael, Victoria, Fellman, Bryan, Meyer, Larissa, Taylor, Taylor, Alvarado, Tina, Grinsfelder, Michaela, Fleming, Nicole, Shafer, Aaron, Cobb, Lauren, Bevers, Michael, Sood, Anil, Mills, Gordon, Coleman, Robert, *Neoadjuvant Olaparib window trial in patients with newly diagnosed BRCA mutant ovarian cancer (LBA 1)*. *Gynecologic Oncology*, 2023. **176**: p. 2-3.

32. Park J, L.J., Lim MC, Kim BG, Kim JW, Kim S, Choi CH, Kim HS, Park SY, Lee JY, *Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D*. *J Immunother Cancer*, 2023. **11**(10).
33. Philipp Harter, M.D., Ph.D., Jalid Sehouli, M.D., Ph.D., Ignace Vergote, M.D., Ph.D., Gwenael Ferron, M.D., Ph.D., Alexander Reuss, M.Sc., Werner Meier, M.D., Ph.D., Stefano Greggi, M.D., Ph.D., Berit J. Mosgaard, M.D., Ph.D., Frederic Selle, M.D., Ph.D., Frédéric Guyon, M.D., Ph.D., Christophe Pomel, M.D., Ph.D., Fabrice Lécuru, M.D., Ph.D., Rongyu Zang, M.D., Ph.D., Elisabeth Avall-Lundqvist, M.D., Ph.D., Jae-Weon Kim, M.D., Ph.D., Jordi Ponce, M.D., Ph.D., Francesco Raspagliesi, M.D., Ph.D., Gunnar Kristensen, M.D., Ph.D., Jean-Marc Classe, M.D., Ph.D., Peter Hillemanns, M.D., Ph.D., Pernille Jensen, M.D., Ph.D., Annette Hasenburg, M.D., Ph.D., Sadaf Ghaem-Maghami, M.D., Ph.D., Mansoor R. Mirza, M.D., Ph.D., Bente Lund, M.D., Ph.D., Alexander Reinthaller, M.D., Ph.D., Ana Santaballa, M.D., Ph.D., Adeola Olaitan, M.D., Ph.D., Felix Hilpert, M.D., Ph.D., and Andreas du Bois, M.D., Ph.D., *Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer*. *N Engl J Med.*, 2021. **385**: p. 2123-2131.
34. Pujade-Lauraine E, S.F., Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mađry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladiëff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A, *Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial*. *Ann Oncol.*, 2023. **34**(12): p. 1152-1164.
35. Harter P, P.P., Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F, *2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer*. *Int J Gynecol Cancer.*, 2022. **32**.
36. Man Jiang, T.L., Guanqun Wang, and Xiaochun Zhang, *Efficacy and safety of pembrolizumab in combination with anlotinib in the treatment of refractory or recurrent high-grade serous ovarian cancer: A phase 2 nonrandomized clinical trial*. *Journal of Clinical Oncology*, 2022. **40**(16).